EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy



Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy



Endocrine Regulations 45(4): 199-204



The aim of the study is to evaluate the changes of bone mineral density (BMD), incidence of pathological fractures and to asses the effect of bisphosphonate therapy in prostate cancer patients (PCa) on androgen deprivation therapy (ADT) with the use of LHRH. In this prospective study bone mass density (BMD) was assessed by dual x-ray absorptiometry (DXA) in 97 PCa patients and 89 patients of compared group. DXA was examined at baseline and patients in the study group were subjected to ADT. PCa patients with osteoporosis were treated by calcium, vitamin D, and bisphosphonate and the subsequent DXA was made after 10 months. All other PCa patients (non-osteoporotic) had DXA examined every 12-14 months. Patients of the study group had significantly lower baseline L1-L4 and total hip BMD (p=0.028, p=0.022). BMD was significantly lower in L1-L4 and total hip (p=0.004, p<0.001, resp.) after 10-14 months and in L1-L4, femoral neck, and total hip (p=0.001, p=0.037, p< 0.001, resp.) after 20-26 months of ADT. After the treatment for osteoporosis with bisphosphonate a significant increase of BMD (p=0.04) was found in a total of 23 patients. Overall, the incidence of fractures after 20-26 months of ADT was 8.5 %. Osteopenia is very common in hormone naive PCa patients. There was a significant loss of BMD after 12 months of ADT which was progressive while the patients were on ADT. Bisphosphonate therapy was effective after 20 months of treatment. The incidence of pathological fractures was 7-fold higher in the study group.

(PDF emailed within 1 workday: $29.90)

Accession: 051845815

Download citation: RISBibTeXText

PMID: 22073949



Related references

Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. Journal of Urology 187(3): 889-893, 2012

Androgen deprivation therapy in patients with prostate cancer and changes in bone mineral density. Journal of Bone & Mineral Research 16(Suppl 1): S243, September, 2001

Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy. Collegium Antropologicum 29(2): 589-591, 2006

Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian Journal of Andrology 6(1): 75-77, 2004

Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocrine-Related Cancer 15(4): 943-952, 2008

Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75(5): 1131-1137, 2010

Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer. In Vivo 32(2): 409-412, 2018

Bone mineral density in prostate cancer patients treated with androgen deprivation therapy; Preliminary results. European Urology Supplements 15(13): E1630-E1631, 2016

Self-reported exercise and bone mineral density in prostate cancer patients receiving androgen deprivation therapy. Journal of the American Association of Nurse Practitioners 26(1): 40-48, 2015

Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy. Journal of Bone and Mineral Metabolism: -, 2018

Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab. Anticancer Research 37(7): 3667-3671, 2017

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. International Journal of Radiation Oncology, Biology, Physics 85(5): 1239-1245, 2013

Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 8(1), 2019

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70(1): 122-126, 2007

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. Journal of Urology 176(3): 972-8; Discussion 978, 2006